Following the release of the latest accountable care organization (ACO) participation numbers from the CMS, the National Association of ACOs (NAACOS) authored its own take on the latest data around the Medicare Shared Savings Program, Medicare’s largest and most prominent value-based payment program serving 11 million patients.
Following the release of the latest accountable care organization (ACO) participation numbers from the CMS, the National Association of ACOs (NAACOS) authored its own take on the latest data around the Medicare Shared Savings Program, Medicare’s largest and most prominent value-based payment program serving 11 million patients. That take was published today in the Health Affairs Blog.
CMS, last year, enacted several changes to the ACO program, emphasizing the need to take on financial risk for assigned patients. When those changes took effect on July 1, participation in Medicare’s preeminent ACO program fell from 561 to 518. While not yet a reason to sound an alarm, the dip in participation in 2019 will be problematic for Medicare if it continues, and policy makers should pay close attention as we move forward. ACOs are the dominant alternative payment model that exists today, and if participation drops following CMS’s changes last year, it threatens years of work to transform our delivery and payment system to better reward value and quality. This year could be an anomaly given the midyear application cycle and ACOs waiting to see how last year’s regulatory changes unfold.
Evidence continues to build that ACOs are helping Medicare lower the rate of spending. More “counterfactual” data, which compares Medicare spending to what spending would be like in the absence of ACOs, are available and all show ACOs are lowering Medicare spending by 1% to 2%, which translates into tens of billions of dollars of reduced Medicare spending when compounded annually. Researchers at Harvard University, the Medicare Payment Advisory Commission, and NAACOS have all done such work.
Medicare ACOs in 2017 showed a continuing trend of ACOs saving money compared to the CMS-set benchmarks. CMS acknowledged “spillover” savings in last August’s proposed Pathways rule, pointing out that ACOs lowered Medicare spending outside the ACO program by $1.8—$4.2 billion in 2016 alone in such ways as lower Medicare Advantage payments.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More